141 related articles for article (PubMed ID: 35172826)
1. Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice.
SheelaNair A; Romanczuk AS; Aogo RA; Haldar RN; Lansink LIM; Cromer D; Salinas YG; Guy RK; McCarthy JS; Davenport MP; Haque A; Khoury DS
Malar J; 2022 Feb; 21(1):49. PubMed ID: 35172826
[TBL] [Abstract][Full Text] [Related]
2. Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice.
Aogo RA; Khoury DS; Cromer D; Elliott T; Akter J; Fogg LG; Nair AS; Liligeto UN; Soon MSF; Thomas BS; Pernold CPS; Romanczuk AS; Laohamonthonkul P; Haque A; Davenport MP
Int J Parasitol; 2018 Oct; 48(12):903-913. PubMed ID: 30176235
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
4. Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo.
Khoury DS; Cromer D; Elliott T; Soon MSF; Thomas BS; James KR; Best SE; Aogo RA; Engel JA; Gartlan KH; Akter J; Sebina I; Haque A; Davenport MP
Int J Parasitol; 2017 Dec; 47(14):913-922. PubMed ID: 28864033
[TBL] [Abstract][Full Text] [Related]
5. Superior Pyronaridine Single-Dose Pharmacodynamics Compared to Artesunate, Chloroquine, and Amodiaquine in a Murine Malaria Luciferase Model.
Okoth WA; Dukes EJ; Sullivan DJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967019
[TBL] [Abstract][Full Text] [Related]
6. Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model.
Henrich PP; O'Brien C; Sáenz FE; Cremers S; Kyle DE; Fidock DA
Antimicrob Agents Chemother; 2014; 58(1):183-95. PubMed ID: 24145526
[TBL] [Abstract][Full Text] [Related]
7. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.
Jiménez-Díaz MB; Ebert D; Salinas Y; Pradhan A; Lehane AM; Myrand-Lapierre ME; O'Loughlin KG; Shackleford DM; Justino de Almeida M; Carrillo AK; Clark JA; Dennis AS; Diep J; Deng X; Duffy S; Endsley AN; Fedewa G; Guiguemde WA; Gómez MG; Holbrook G; Horst J; Kim CC; Liu J; Lee MC; Matheny A; Martínez MS; Miller G; Rodríguez-Alejandre A; Sanz L; Sigal M; Spillman NJ; Stein PD; Wang Z; Zhu F; Waterson D; Knapp S; Shelat A; Avery VM; Fidock DA; Gamo FJ; Charman SA; Mirsalis JC; Ma H; Ferrer S; Kirk K; Angulo-Barturen I; Kyle DE; DeRisi JL; Floyd DM; Guy RK
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5455-62. PubMed ID: 25453091
[TBL] [Abstract][Full Text] [Related]
8. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
9. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo.
Vivas L; Rattray L; Stewart L; Bongard E; Robinson BL; Peters W; Croft SL
Acta Trop; 2008 Mar; 105(3):222-8. PubMed ID: 18279817
[TBL] [Abstract][Full Text] [Related]
10. Malaria parasite clearance.
White NJ
Malar J; 2017 Feb; 16(1):88. PubMed ID: 28231817
[TBL] [Abstract][Full Text] [Related]
11. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.
Rueangweerayut R; Phyo AP; Uthaisin C; Poravuth Y; Binh TQ; Tinto H; Pénali LK; Valecha N; Tien NT; Abdulla S; Borghini-Fuhrer I; Duparc S; Shin CS; Fleckenstein L;
N Engl J Med; 2012 Apr; 366(14):1298-309. PubMed ID: 22475593
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium berghei K13 Mutations Mediate
Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays.
Kurth F; Pongratz P; Bélard S; Mordmüller B; Kremsner PG; Ramharter M
Malar J; 2009 Apr; 8():79. PubMed ID: 19389221
[TBL] [Abstract][Full Text] [Related]
14. Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
Gaur AH; Panetta JC; Smith AM; Dallas RH; Freeman BB; Stewart TB; Tang L; John E; Branum KC; Patel ND; Ost S; Heine RN; Richardson JL; Hammill JT; Bebrevska L; Gusovsky F; Maki N; Yanagi T; Flynn PM; McCarthy JS; Chalon S; Guy RK
EBioMedicine; 2022 Jun; 80():104065. PubMed ID: 35598441
[TBL] [Abstract][Full Text] [Related]
15. Review of pyronaridine anti-malarial properties and product characteristics.
Croft SL; Duparc S; Arbe-Barnes SJ; Craft JC; Shin CS; Fleckenstein L; Borghini-Fuhrer I; Rim HJ
Malar J; 2012 Aug; 11():270. PubMed ID: 22877082
[TBL] [Abstract][Full Text] [Related]
16. Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria.
Moradin N; Torre S; Gauthier S; Tam M; Hawari J; Vandercruyssen K; De Spiegeleer B; Fortin A; Stevenson MM; Gros P
Malar J; 2016 May; 15(1):260. PubMed ID: 27150250
[TBL] [Abstract][Full Text] [Related]
17. Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial.
Byakika-Kibwika P; Nyakato P; Lamorde M; Kiragga AN
Malar J; 2018 Oct; 17(1):400. PubMed ID: 30376860
[TBL] [Abstract][Full Text] [Related]
18. [The blood schizontocidal effects of pyronaridine, amodiaquine, mefloquine and qinghaosu on mice infected with Plasmodium berghei].
Ye XY; Shao BR; Chu YH
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1992; 10(2):120-3. PubMed ID: 1394908
[TBL] [Abstract][Full Text] [Related]
19. Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.
Gimode WR; Kiboi DM; Kimani FT; Wamakima HN; Burugu MW; Muregi FW
Malar J; 2015 Jan; 14():38. PubMed ID: 25627576
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
Sagara I; Beavogui AH; Zongo I; Soulama I; Borghini-Fuhrer I; Fofana B; Camara D; Somé AF; Coulibaly AS; Traore OB; Dara N; Kabore MJ; Thera I; Compaore YD; Sylla MM; Nikiema F; Diallo MS; Dicko A; Gil JP; Borrmann S; Duparc S; Miller RM; Doumbo OK; Shin J; Bjorkman A; Ouedraogo JB; Sirima SB; Djimdé AA
Lancet Infect Dis; 2016 Feb; 16(2):189-98. PubMed ID: 26601738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
